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Traditionally, the ability to deliver large doses of ionizing radiation to a tumor has been 
limited by radiation-induced toxicity to normal surrounding tissues. This was the initial 
impetus for the development of conventionally fractionated radiation therapy, where
large volumes of healthy tissue received radiation and were allowed the time to repair the 
radiation damage. However, advances in radiation delivery techniques and image guid-
ance have allowed for more ablative doses of radiation to be delivered in a very accurate, 
conformal, and safe manner with shortened fractionation schemes. Hypofractionated 
regimens with photons have already transformed how certain tumor types are treated 
with radiation therapy. Additionally, hypofractionation is able to deliver a complete course 
of ablative radiation therapy over a shorter period of time compared to conventional 
fractionation regimens making treatment more convenient to the patient and potentially 
more cost-effective. Recently, there has been an increased interest in proton therapy 
because of the potential further improvement in dose distributions achievable due to 
their unique physical characteristics. Furthermore, with heavier ions the dose confor-
mality is increased and, in addition, there is potentially a higher biological effectiveness 
compared to protons and photons. Due to the properties mentioned above, charged 
particle therapy has already become an attractive modality to further investigate the
role of hypofractionation in the treatment of various tumors. This review will discuss
the rationale and evolution of hypofractionated radiation therapy, the reported clinical 
success with initially photon and then charged particle modalities, and further potential 
implementation into treatment regimens going forward.
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iNTRODUCTiON
After the discovery of X-rays in 1895 and radioactivity in 1896, initial radiation cancer treatments 
were mostly hypofractionated. Treatments were limited in giving higher doses to the skin and super-
ficial structures than to a deeper tumor target. Quality assurance measures were lacking to ensure 
accurate dose deposition. These approaches lead to tumor responses, however, with significant 
late tissue effects. Despite these shortcomings, hypofractionation remained the primary treatment 
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schedule due to patient convenience and technical considerations 
with treatment delivery.
Early radiotherapy pioneers, including Friedrich Dessauer, 
sought to address the limitations with the state of technology 
for delivering hypofractionated treatments. In 1905, Dessauer 
proposed that clinical outcomes could be improved with the 
application of homogeneous dose to the tissue and eventually 
leading to the formulation of ideas of multibeam or multisource 
irradiation (1).
At the same time, Claudius Regaud was performing his seminal 
experiments relating to the irradiation of the testis. He observed 
that cells undergoing mitosis were more sensitive to radiation, 
whereas the more differentiated cells were less sensitive (2). This 
work lead to the “Law of Bergonie and Tribondeau” stating that 
the effects of irradiation on cells are more intense, the greater their 
reproductive activity, the longer their mitotic phases, and the less 
differentiated, forming the biological basis for fractionation (3).
By the 1920s, despite the advocacy of Regaud, Antoine Béclère, 
and Henri Coutard, multiple fractionated treatments were still 
less popular than hypofractionated treatments. The approach 
promoted by Ludwig Seitz and Hermann Wintz, favoring 
intensive short courses of radiotherapy for treatment of cervical 
cancer, was widely adopted (4).
In 1932, Henri Coutard presented his landmark findings at 
the American Congress of Roentgenology, demonstrating that 
protracted-fractionated external beam therapy had cured deep 
tumors with significantly less toxicity previously seen (5). From 
this point forward, radiation oncologists across the world mostly 
abandoned hypofractionated as a method for curative treatment. 
Interestingly, Coutard believed in both approaches stating that 
choice of fractionation should depend on the initial volume of 
the target (small targets warrant hypofractionation, whereas large 
should be more protracted) (6).
It took until the 1950s, when Lars Leksell, a neurosurgeon, 
broke from the perceived wisdom of conventionally fractionated 
radiotherapy (CFRT) by using large-dose single sessions of radia-
tion delivery in the central nervous system (7). In conjunction 
with a radiation physicist, Borge Larsson, they created the first 
Gamma Knife (Elekta AB, Stockholm, Sweden). Although a 
single large-dose radiation treatment was historically intolerable, 
Leksell’s approach defied conventional wisdom by its technology 
and conduct. Unlike CFRT, which often irradiates much larger 
volumes of normal tissue to the prescription dose than the tumor 
itself if a limited number of beams are utilized, Leksell’s stereo-
tactic radiosurgery surgery (SRS) went to great lengths to avoid 
delivering high dose to non-targeted tissues. Whatever normal 
tissue was included, either by being adjacent to the target or by 
inferior dosimetry, was likely damaged. However, if this damaged 
tissue was small in volume or non-eloquent, the patient did not 
suffer clinically apparent toxicity, even as a late event.
Building upon these results, investigators in Sweden at the 
Karolinska Institute in Sweden by Lax and Blomgren, departed 
from the established traditions of CFRT and began to explore the 
use of alternative hypofractionated radiation treatment regimens 
for the lung, liver, and selected other malignant extracranial 
tumors. Furthermore, technical advancements in linear accelera-
tors allowing for the delivery of increased beam energies made 
deep-seeded tumors more accessible with less toxicity. They 
constructed a stereotactic body frame that would simultaneously 
enable comfortable and reliable immobilization and dampening 
of respiratory motion, treating patients with extracranial, local-
ized tumors with ablative doses of radiation that ranged from 7.7 
to 45 Gy in 1–4 fractions (8). At the same time in Japan, Uematsu 
and colleagues developed technologies to deliver stereotactic 
radiation to lung tumors (9). Initially, the treatments were called 
extracranial stereotactic radioablation, and later stereotactic 
body radiation therapy (SBRT) (10, 11). More recently, the 
descriptive term stereotactic ablative radiotherapy (SABR) has 
been used (12).
Radiobiologic Modeling of High Dose per 
Fraction with Photons
Classical understanding of the mechanisms of radiation induced 
tumor cell killing centers on the hypothesis that DNA is the main 
target of ionizing radiation, leading to single- and double-strand 
breaks. Different mathematical models have been developed to 
compare tumor control and normal tissue toxicity profiles for 
various radiation schedules and fraction sizes. The most com-
monly used is the linear quadratic (LQ) model, which describes 
cell killing as a single hit versus double hit hypothesis, where the 
linear cell kill is expressed by the α component, while the quad-
ratic cell kill is expressed by the β component (13). The α/β ratio 
is obtained from isoeffect curves using the survival fractions of a 
cell line at different doses per fraction (14). This ratio is primarily 
utilized to predict the clinical effects in response to changes in 
fraction size. With regard to tumors, a high α/β ratio predicts 
higher sensitivity to CFRT, while a lower α/β ratio predicts lower 
sensitivity to CFRT. Most tumors typically possess a high α/β 
ratio (~8–10) relative to most normal tissues, which demonstrate 
lower α/β ratios (~1–4).
Not all hypofractionated radiotherapy is ablative. In general, 
ablation occurs at dose levels that correspond to the exponential 
(linear region on a logarithmic scale) portion of the cell-survival 
curve, which would generally involve daily dose levels of >8 Gy. 
Below this dose range, cells have more capacity to repair. The 
logarithm of cell survival as a function of dose in the lower-dose 
region exhibits a curviness called the shoulder. More conventional 
and non-ablative hypofractionated radiotherapy is delivered on 
the shoulder. The range of 2.25–8 Gy per fraction, still consid-
ered hypofractionated, has mostly been used for palliation of 
metastatic disease. More recently, though, investigators treating 
common diseases, such as breast and prostate cancer, have used 
non-ablative hypofractionation in patients with curable tumors. 
This was partly for the cost savings associated with fewer overall 
fractions, but in some cases such hypofractionation has a biologi-
cal rationale for improving the therapeutic ratio. A summary of 
the degrees of hypofractionated radiotherapy is shown in Table 1.
Biological effective dose (BED) quantifies the true biological 
dose delivered by a particular combination of dose per fraction 
and total dose to a certain tissue characterized by a specified α/β 
ratio. Based on experimental and clinical data, the LQ model 
seems to predict BED accurately for fraction sizes <3.25 Gy (15). 
Due to the fact that typical doses for SBRT/SABR fall outside of 
TABLe 1 | various daily fractionation options.
Fractionation regimen Typical dose per fraction (Gy)
Conventionally fractionated radiotherapy 1.5–2.0
Hypofractionated radiotherapy >2.0–8.0
Ablative radiotherapy >8.0
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this range, the LQ model breaks down as it does not accurately 
predict the BED for abbreviated hypofractionated regimens 
(15–18). Development of more accurate models to predict the 
responses of tumors to hypofractionated radiotherapy have been 
attempted. The universal survival curve, modified linear quad-
ratic model (LQL), and the generalized LQ model all have shown 
better radiobiological modeling of high dose per fraction than 
the LQ model, with moderate success at maintaining accuracy 
within the conventionally fractionated range (15, 17, 19). These 
models primarily predict the tumor control to hypofractionated 
radiotherapy; however, better estimation of normal tissue toxicity 
with larger doses per fraction is required.
Limitations to predict clinically relevant endpoints exist in 
simple radiobiological modeling due to the presence of additional 
factors, including dose rate, period of time over which treatment 
is delivered, tissue type irradiated, and competing cell death 
mechanisms besides DNA damage. These may include immu-
nological activation mediated by the release of antigens, damage 
to cell membranes and organelles, and additional mechanisms 
related to ablative therapy (20).
Several groups have described tissues and their radiation 
response according to the organization of the smallest functional 
subunit (21, 22). Structurally defined tissues can only repair radia-
tion damage by recruiting their own stem cells and have a lower 
radiation tolerance per functional subunit. Generally, organs 
comprised such structurally defined subunits, also called parallel 
functioning tissues, and are large organs, such as the peripheral 
lung and liver. Parallel organs display significant redundancy in 
the number of subunits performing the same function to overcome 
the poor tolerance to damage. By contrast, tissues made up of 
predominately of structurally undefined subunits are much more 
tolerant of radiation damage per subunit because of their ability 
to recruit clonogenic cells from neighboring tissues for repair. 
Organs made up of structurally undefined subunits, such as the 
esophagus, major ducts and airways, and spinal cord, are referred 
as serially functioning tissues and perform critical functions act-
ing as a conduit. Despite possessing a higher radiation tolerance, 
if a section of a serially functioning tissue is damaged anywhere 
along its length, all downstream function may be affected (23). 
The potential to elicit such tissue injury when utilizing ablative 
doses is a major consideration needed to be taken into account 
when developing treatment plans.
Technical and Safety Considerations of 
Ablative Therapy with Photons
Abbreviated hypofractionated treatments require highly confor-
mal dose distributions that fall off very rapidly in all directions, 
which require the use of multiple shaped beams (24, 25). Most 
modern SBRT/SABR treatments utilize 10–12 highly collimated 
beams or multiple conformal arcs. Effort should be made to cre-
ate truly isotropically decreasing dose gradients around targets, 
within the limitations due to potential collisions between the 
patient or couch and the accelerator head.
The gross tumor volume should be derived by incorporating 
advanced imaging techniques to assist in the differentiation 
between tumor and adjacent normal tissue. The planning treat-
ment volume comprises the final target for high-dose conformal 
coverage and includes an accounting for organ motion. Limitation 
of the high- and intermediate-dose spillage should be attempted 
with careful determination of the volume they incorporate. Such 
spillage should be prioritized to avoid potential adjacent serially 
functioning tissues to reduce potential injury and downstream 
effects.
In summary, the defining characteristics of SBRT/SABR 
include the following (23): (1) secure immobilization avoiding 
patient movement for the typical long treatment sessions; (2) 
accurate repositioning from simulation to treatment; (3) minimi-
zation of normal tissue exposure attained by using multiple (e.g., 
10 or more) or large-angle arcing small aperture fields; (4) rigor-
ous accounting of organ motion; (5) stereotactic registration (i.e., 
via fiducial markers or surrogates) of tumor targets and normal 
tissue avoidance structures to the treatment delivery machine; 
and (6) ablative dose fractionation delivered to the patient with 
subcentimeter accuracy.
CLiNiCAL ReSULTS OF 
HYPOFRACTiONATiON wiTH PHOTONS
Non-Small Cell Lung Cancer
For patients with medically inoperable non-small cell lung cancer 
(NSCLC), dose escalation using conventional fractionation was 
initially explored to improve the probability of local control. 
Radiation Therapy Oncology Group (RTOG) Protocol 7301 
investigated multiple dosing regimens for patients with T1-3 
N0-2 disease, including 40  Gy delivered in a split regimen of 
two courses of 20 Gy delivered in 5 fractions (40 Gy total in 10 
fractions) with a 2-week break between courses, and continuous 
regiments escalating the dose from 40 to 60 Gy. The failure rate 
within the irradiated volume was 48% in the 40 Gy continuous 
regimen, 38% for the 40 Gy split course and 50 Gy regimen, and 
27% in the 60 Gy continuous regimen (26). RTOG Protocol 9311 
then escalated doses from 65 to 90.3  Gy using 3D conformal 
radiation therapy in inoperable patients, and found that treat-
ment could safely be delivered in daily fraction sizes of 2.15 Gy 
to a total dose of 77.4 Gy, or 83.8 Gy provided that the volume of 
lung receiving 20 Gy could be constrained to less than 25% of the 
total lung volume. The study attained locoregional control rates 
at 2 years of 55–78% at the maximum tolerated dose (MTD) (27).
In order to continue to improve LC and OS in this patient 
population, protocols have sought to improve the therapeutic 
ratio with the addition of chemotherapy or by changing the dose 
per fraction. Researchers at Indiana University reported a Phase 
1 study in which patients with T1–T2 N0 NSCLC were treated 
with escalating doses of SBRT/SABR, starting at 24 Gy in three 
fractions and increasing to 60 Gy (for T1 lesions) or 72 Gy (for T2 
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lesions) in three fractions to determine the MTD. The MTD was 
not reached for T1 lesions at 60 Gy, and for T2 lesions an MTD of 
66 Gy was established based on bronchitis, pericardial effusion, 
hypoxia, and pneumonitis. Crude rates of local failure were 21% in 
both the T1 and T2 cohorts, and a dose–response was noted with 
only one local failure observed with fraction sizes of >16 Gy per 
fraction (10, 28). These doses were calculated without correction 
for tissue inhomogeneity; subsequent doses used inhomogeneity 
correction and, as a result, appear slightly lower.
A subsequent Phase 2 multicenter trial (RTOG 0236) further 
evaluated the toxicity and efficacy of SBRT in a high-risk popula-
tion of patients with T1-2aN0 (lesions <5 cm in size) early stage, 
medically inoperable NSCLC. Doses of 54 Gy in three fractions 
were delivered, and an estimated 3-year local control rate of 97.6% 
was observed, with an overall survival rate of 55.8% at 3 years 
(29). Based on this study, SBRT/SABR is now the standard of care 
for medically inoperable early-stage NSCLC or those patients 
who refuse surgery. Further work is being done to optimize dose 
delivery for early stage NSCLC; the RTOG conducted RTOG 
Protocol 0915, a randomized Phase II study that compared two 
different SBRT/SABR treatment schedules for medically inoper-
able patients with Stage I peripheral NSCLC, in which patients 
were randomized to receive 34 Gy in a single fraction or 48 Gy 
in four daily consecutive fractions of 12  Gy per fraction. This 
protocol is now closed to accrual, and final results are pending; 
preliminary data suggest that 34 Gy may be more efficacious with 
respect to local control and equivalent in toxicity profile, and a 
comparison of 34 Gy in one fraction to 54 Gy in three fractions 
is planned.
Primary Liver Cancer
In a phase I feasibility trial at Indiana University, patients with 
hepatocellular carcinoma (HCC) were treated with dose escala-
tion from 36  Gy in three fractions to a total dose of 48  Gy in 
three fractions if dose-limiting toxicities were not suffered (30). 
Patients were eligible for this trial if they had Child–Pugh score 
A or B, a solitary tumor <6 cm in size or three lesions with total 
diameter <6 cm and adequate liver function. Key normal tissue 
constraints were that one-third of the uninvolved liver received 
≤10 Gy for Child–Pugh class A patients and that one-third of the 
uninvolved liver received ≤15 Gy for Child–Pugh class B patients. 
In this study, the dose was successfully escalated to patients with 
Child–Pugh class A to 48 Gy in three fractions without reaching 
dose-limiting toxicity. However, in patients with Child–Pugh 
class B cirrhosis, the maximum tolerated dose was 40 Gy in five 
fractions due to two patients suffering Grade 3 liver toxicity. With 
long-term follow-up, the Indiana experience found positive rates 
of 2-year local control of 90% among the treated population. There 
were no long-term grade 3 or higher non-hematologic toxicities 
and 20% of patients were found to experience progression in the 
Child–Pugh score at 3 months (31).
A second key phase I/II trial was performed by Princess 
Margaret University and the University of Toronto (32). In this 
trial, patients with Child–Pugh score A with no more than five 
liver tumors with a maximal dimension of 15 cm were enrolled. 
Patients in this trial were treated to a dose of 30 to 54 Gy in six 
fractions, with the maximum effective irradiated liver volume of 
60%. No patients in this trial suffered classic radiation-induced 
liver disease (RILD) or dose-limiting toxicity, with a decline in 
Child–Pugh score at 3 months occurring in 29% of the cohort. 
Like the Indiana experience, the local tumor control was excellent 
at 87% at 1  year. These two trials provide data for the efficacy 
for SBRT/SABR in the setting of well-controlled and designed 
clinical trials.
While these studies were limited to patients with preserved 
to mildly elevated liver function, there is evidence for the treat-
ment of patients with Child–Pugh B7 or B8 with SBRT/SABR 
as well. The Princess Margaret group performed a prospective 
study with patients having Child–Pugh B7 or 8 with less than 
10 cm of HCC tumor (33). Patients received a median dose of 
30 Gy in five fractions; however, as expected with their more 
fragile liver function, 63% of the cohort had a decline in their 
Child–Pugh score at 3 months. Sorafenib is a tyrosine kinase 
inhibitor that was used in patients with advanced HCC, show-
ing an improvement in overall survival compared to placebo. 
Currently, an RTOG trial 1112 is enrolling patients with 
advanced stage HCC to daily sorafenib versus SBRT/SABR 
alone followed by daily sorafenib. The primary endpoint of 
the trial is overall survival with secondary endpoints, evaluat-
ing the safety profile of SBRT/SABR plus sorafenib. This trial 
will potentially further expand the utilization of SBRT/SABR 
patients with advanced HCC.
Prostate Cancer
Recent analysis and review of clinical outcomes, primarily after 
treatment with brachytherapy, argue for a low α/β for prostate 
cancer of ~1.5 (34–38). Several recent clinical trials were designed 
with the explicit assumption of this low α/β ratio by utilizing 
more hypofractionated regimens in comparison with conven-
tional schedules (39–44). Altogether, these trials show that the 
treatment can be delivered much more quickly and conveniently 
using equivalent effective doses with hypofractionation without 
compromising PSA control or significant toxicity so long as 
careful technique and normal tissue dose tolerance is respected. 
Building upon this premise, even more abbreviated hypofraction-
ated approaches (6.5–10 Gy per fraction) have been investigated.
The Virginia Mason Medical Center published one of the first 
experiences with prostate SBRT/SABR, describing their results 
from a phase I/II trial delivering 33.5 Gy in five fractions (45). 
Median follow-up was 41 months. There was one acute grade 3 
urinary toxicity (urinary retention requiring catheterization) and 
no acute grades 4–5 toxicities. Late grade 2 GU and GI toxicity 
rates were 20 and 7.5%, respectively, with no grade 3 or higher 
toxicities. Four-year actuarial freedom from biochemical recur-
rence (FFBR) was 90%.
The feasibility of increasing SBRT/SABR dose was investigated 
at Stanford University in a phase II trial (46). 36.25 Gy in five frac-
tions of 7.25 Gy was delivered to the prostate plus a 3–5 mm mar-
gin. In 67 patients with low to intermediate-risk features (Gleason 
score 3 + 3 or 3 + 4, PSA ≤10 ng/mL, and clinical stage ≤T2b), 
there were no grade 4 or higher toxicities. Late grades 2 and 3 GU 
toxicity rates were 5 and 3.5%, respectively. Late grade 2 GI toxic-
ity was 2% with no grade 3 or higher toxicities seen. Patients who 
received QOD treatments were less likely to experience grades 
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1–2 GI and GU toxicities than those who received QD treatments. 
Four-year PSA relapse-free survival was 94%.
The largest prospective study of prostate SBRT/SABR is from 
the Winthrop University Hospital (47). A total of 304 patients 
(69% low-risk, 27% intermediate-risk, 4% high-risk) were 
treated. The first 50 patients received 35 Gy in five fractions of 
7 Gy with the subsequent 254 patients receiving 36.25 Gy in five 
fractions of 7.25 Gy. Lower-dose patients had a median follow-up 
of 30 months and the higher-dose patients had a median follow-
up of 17 months. There were no grades 3–4 acute complications. 
Late grade 2 GU and GI toxicity was 14 and 7%, respectively. 
Five patients had late grade 3 GU toxicity with no late grades 
4–5 toxicities. For patients who were potent prior to treatment, 
75% stated that they remained sexually potent. Actuarial 5-year 
biochemical recurrence-free survival was 97% for low-risk, 90.7% 
for intermediate-risk, and 74.1% for high-risk patients.
A recent pooled analysis of 1100 patients from prospective 
phase II trials using SBRT/SABR for the treatment of prostate 
cancer in which a median dose of 36.25  Gy was delivered in 
four to five fractions demonstrated a 93% 5-year biochemical 
relapse-free survival rate for all patients (95% for low-risk, 84% 
for intermediate-risk, and 81% for high-risk) with favorable 
long-term patient reported outcomes with respect to urinary and 
bowel functions (48, 49).
Compared to the prior studies using similar dose fractionation 
regimens, a multicenter phase I/II trial investigation using signifi-
cantly higher doses was performed (50). In the phase I portion, 45 
patients, in 3 cohorts of 15, were treated with 45, 47.5, and 50 Gy 
in five equal fractions, respectively. No dose-limiting toxicities 
(grades 3–5) occurred within the first 90  days post-treatment. 
GI grade ≥2 and grade ≥3 toxicity occurred in 18 and 2%, 
respectively, and GU grade ≥2 and grade ≥3 toxicity occurred 
in 31 and 4%, respectively. Initial PSA control was 100%. These 
encouraging results led to the further enrollment on the phase II 
trial at the 50 Gy dose level studying late toxicity. An additional 
46 patients were enrolled for a total of 91 (64% intermediate-risk 
and 36% low-risk). With a median follow-up of 42 months, PSA 
control remained at 99% (51). Ultimately, dose escalation to treat 
prostate cancer is limited by toxicity to the bladder or rectum. 
As reported in an update by Kim et al., the toxicity profile was 
favorable in the initial phase I results; however, in the phase II 
portion, the profile changed and five patients (10.6%) developed 
high-grade rectal toxicity (52).
HYPOFRACTiONATiON wiTH PROTON 
AND HeAvieR iON THeRAPY
Background
Protons and other heavier charged particles offer some theoretical 
advantages over photons that can be utilized in hypofractionated 
dose delivery regimes.
As charged particles move in tissue, they deposit energy (dose) 
and cause ionization of tissue and create highly reactive free 
radicals. This has two important consequences. One is that after 
traversing tissue for a certain depth, they impart all of their initial 
kinetic energy and they stop moving. In other words, charged 
particles have a finite range in tissue, unlike a photon beam, that 
can only be exponentially attenuated but not stopped. The second 
consequence is that these free radicals cause biological damage. 
As more dose is deposited, more ionization occurs generating 
more free radicals, leading to a higher biological damage. The 
amount of absorbed dose per unit track length [called the linear 
energy transfer (LET) to tissue] increases as they lose speed 
along their paths. At first, very gradually in the tissue entrance 
region where particles are moving with speed close to the speed 
of light, but then very rapidly toward the end of their range where 
they substantially slow down so that a peak of deposited dose 
occurs at a depth proportional to the initial kinetic energy of the 
charged particle. Beyond this peak, no further significant dose 
is deposited. This scientific phenomenon was described and 
experimentally discovered by William Bragg at that time (53). 
As mentioned above, the range in tissue is proportional to initial 
kinetic energy of the particles. Hence, particle accelerators are 
needed to get the initial speed high enough so they reach even 
deep seeded tumors. In 1930, the American physicist Ernest O. 
Lawrence and his associates were the first to invent a cyclotron to 
accelerate protons. Since then, the technology has substantially 
improved and many proton cyclotrons and particle synchrotrons 
have been built to reach energies high enough for cancer treat-
ment applications.
The idea to use proton and charged particle beams for cancer 
treatment came in 1946, when Wilson wrote his seminal paper 
(54). He realized that the fundamental difference in dose as a 
function of depth (depth–dose curve) of proton and heavy-
charged particles, in comparison with photons, can be used to 
spare healthy tissue at the tissue entrance region where smaller 
amount of energy is released, but to achieve high tumor control at 
the peak, where much larger amount of the beam energy is being 
released. Also healthy tissue can be spared beyond where no 
protons are present since they already stopped at the peak region. 
The first proton patient was treated in 1954 at Lawrence Berkeley 
National Laboratory (LBNL) nuclear research facility and the first 
clinical center to use proton-based therapy was based at Loma-
Linda and initially used to treat pituitary hormone suppression in 
metastatic breast carcinoma.
Ions heavier than a proton were first used for cancer therapy 
in the 1970s after Cornelius Tobias hypothesized that they could 
provide additional clinical advantages (55). Heavier ions have 
reduced lateral scattering compared with protons. This translates 
into faster lateral dose fall off (called sharper lateral penumbra) 
leading to a better ability to conform dose to the target region; 
hence, higher therapeutic doses can be prescribed to tumors 
located in near proximity to radiosensitive organs at risk. Another 
huge advantage of heavier ions is that they interact with tissue they 
create a small amount of radioactive positron emitting isotopes 
that can be imaged in PET/CT scanners providing direct in vivo 
information about the spatial distribution of delivered dose. The 
higher ionization density created by heavier ions leads to their 
increased radiobiological effects on tissues. Initial radiobiology 
research and clinical treatment used beams of nuclei of helium, 
carbon, neon, silicon, and argon atoms; however, most of the 
clinical experiences with ions heavier than protons involves car-
bon, because this particle has approximately the same biological 
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potency as photons or protons in the tissue entrance region and 
three to four times larger potency in the Bragg peak region even 
if the same dose was absorbed (56).
Radiobiological Modeling of 
Hypofractionation with Protons and 
Heavier ions
A generalized statement is that the higher the electric charge of 
the charged particle, the higher the energy loss per unit track 
length (quadratically higher) while penetrating tissue. Therefore, 
the LET is 36 times higher for carbon ions compared with protons 
when they move with the same speed (57). The increased LET 
has a consequence of increased biological potency expressed by 
relative biological effectiveness (RBE) that is defined as a quotient 
describing how many times more dose is needed to be delivered 
by photons than by charged particles to achieve the same bio-
logical endpoint. Clinical proton beams are of low LET with a 
RBE very close to that of high-energy photons. Recently, the 
International Commission on Radiation Units and Measurement 
(ICRU) proposed a RBE of 1.10 regardless of depth in tissue for 
proton therapy (58). The RBE of heavier ions to be clinically used 
is still under investigation (59–61).
As mentioned above, another difference between protons and 
carbon is that the RBE for carbon ions varies, with an increase in 
the Bragg peak region. This increase in RBE needs to be accounted 
for in treatment planning in order to have an appropriate pre-
scribed dose (59, 62, 63). Calculation of the RBE is complex in 
that it depends on multiple factors, including the particle species, 
ion beam energy, dose, tissue type being irradiated, and biological 
endpoint. An accurate description of RBE dependence on dose 
is even more critical in the setting of hypofractionation (64–66). 
Recently, an excellent review of how variation of the RBE of 
ion beams in the setting of hypofractionated radiotherapy was 
presented by Friedrich et al. (60). In general, increasing the dose 
per fraction leads to lower RBE of the tumor and normal tissue 
(67). Data suggest that the RBE of the tumor decreases more 
slowly than the RBE of the normal tissue (68, 69). Therefore, 
hypofractionated heavy-ion treatment can be used to spare the 
organs at risk while escalating dose to the tumor.
Technical Considerations of 
Hypofractionation with Protons and 
Heavier ions
Very tight prescription dose conformity to the target and very 
sharp dose fall off between tumor tissue and healthy tissue are 
essential for hypofractionation approach to succeed. As described 
in Section “Background,” the physics of heavy-charged particle 
interactions with tissue theoretically offers superior solutions to 
achieve both of these goals with respect to photons. It is the beam 
delivery techniques that differ between photons and charged 
particles. Heavy-charged particle therapy physics and engineer-
ing has yet to develop the most advanced therapy, namely the 
equivalent of the volumetric photon arc therapy that would fully 
utilize the physics advantages of heavier charged particles.
Most particles centers are currently using scattering tech-
niques with energy modulators, patient-specific collimators, and 
compensators to spread out protons and carbon ions both in 
longitudinal and lateral directions for treatment. Scattering beam 
delivery is easier for planning and quite robust in the treatment of 
a moving target. There are two major downsides of this technique. 
It requires the usage of patient and beam direction-specific colli-
mators and compensators, which limits the number of irradiation 
directions that could practically be feasible. Another downside of 
this approach is that the dose to the preceding normal tissue in 
the entrance path is very difficult to modulate and conform to the 
target. It is, therefore, higher compared with modern beam scan-
ning techniques, leading potentially to an increased risk in the 
development of secondary malignancies and other healthy tissue 
toxicities. Recently, more active beam delivery techniques, spot 
scanning or raster scanning, have been developed. Spot scanning 
is superior to passive beam delivery in terms of the improved 
dose profile and the reduced amount of material in the beam 
line, which decreases the leakage or radiations and neutrons (56). 
However, the capability to treat moving targets with scanning 
beams remains a challenge since longitudinal (in the direction 
of energy) beam modulation is still relatively slow. Approaches, 
such as target motion tracking, have been proposed (70) with 
systems capable of fast energy change of individual spots. Real-
time detection of tumor and surrounding organ motion is vital 
for such a technique to succeed and remains a problem.
Another important consideration is how to deliver multidirec-
tional particle beams. As mentioned above, highly conformal rapid 
dose fall off that is achieved with SABR photon therapy relies on the 
utilization of multiple beam angles. If the same is used with heavy-
charged particles, both high-dose and intermediate-dose volume 
regions outside of the targeted area can substantially be reduced. 
Furthermore, with photons, the size of tumor targets (radius, r) 
to which high dose hypofractionation can be applied is limited to 
2–3 centimeters in diameter. This is due to the fact that even for 
relatively small (Δr) region of high dose over spillage, the volume 
receiving the high dose grows quadratically with r and linearly with 
Δr. Doubling the target size “r” would require to reduce the high 
dose over spillage Δr by factor of 4 to keep the same volume of high 
dose over spillage. This is impossible to achieve with photons, but 
heavier charged particles have the Δr intrinsically much lower than 
photons both in front, beyond, and lateral to tumors.
Currently, many heavy-ion centers used fixed angle beams 
from different directions and tilt the patient’s couch to provide 
different entrance angles, but multiple CT scans and treatment 
plans are necessary and the magnitude of patient tilt is limited. 
The use of a rotating gantry would allow for a beam delivery from 
any angle. Currently, the first heavy-ion rotating gantry is in use 
at the Heidelberg Ion Therapy Center (HIT) in Germany and 
another is currently under construction at the National Institute 
of Radiological Sciences (NIRS) in Japan. Further results from 
these centers should help to shed light on if the clinical advan-
tages live up to the theoretical dosimetric advantages listed above.
Clinical Results of Hypofractionation with 
Protons and Heavier ions
The higher conformal beam delivery with particles, compared to 
photons, allows for dose escalation to the tumor without exposing 
the adjacent organs at risk to higher doses (56, 71). Compared with 
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photon therapy, it is assumed that using particles results in a lower 
integral dose to normal tissues and a lower whole-body neutron 
exposure (72). To date, more hypofractionated approaches have 
been utilized in carbon-ion therapy compared to proton therapy, 
where more conventional fractionation regimens are employed 
(57). Additionally, most of the clinical data on proton and carbon 
therapy were collected from patients treated with passively scat-
tered beams. More recently, active scanned proton and carbon-
ion beams have been developed and used for clinical treatment.
Non-Small Cell Lung Cancer
For early stage I peripheral NSCLC tumors, local control rates 
are high for hypofractionated photons. The use of protons and 
carbon ions for the treatment of early stage tumors have been 
studied to avoid lung toxicity by sparing normal lung tissue while 
facilitating escalated dose to the tumor.
At Loma Linda University, medically inoperable patients with 
clinical T1–T2, N0, M0 NSCLC were treated with hypofrac-
tionated proton therapy (73). The dose delivered was escalated 
from 51 to 60 GyE, then to 70 GyE in 10 fractions over 2 weeks. 
Four-year local control for T1 tumors treated with either 60 or 70 
GyE were 86 and 91%, respectively. Decreased control rates were 
seen for T2 tumors, 45 and 74%, respectively. Good outcomes 
were seen for patients with peripheral T1 tumors, with 4-year 
local control of 96%, disease-specific survival of 88%, and overall 
survival of 60%. No treatment-related adverse events of grade 2 
or higher were observed.
Nihei et al. treated 37 inoperable patients with Stage I NSCLC 
(74). A total dose of 70 to 94 GyE was delivered in 20 fractions 
in 4–5  weeks. Two-year local control rates for Stages 1A and 
1B tumors were 100 and 90%, respectively. Three patients (8%) 
experienced grade 3 pulmonary toxicity.
Hata et al. treated 21 patients (11 with Stage 1A and 10 with 
Stage 1B) NSCLC were treated with 50 GyE (three patients) or 
60 GyE (18 patients) in 10 fractions over 15 days (75). Two-year 
local control rates were 100% for Stage 1A and 90% for Stage 1B, 
respectively. The overall and cause-specific survival rates in all 
patients were 74 and 86% at 2 years, respectively. No grade 3 or 
higher toxicities were observed.
The initial dose-escalation experience with treating Stage I 
NSCLC tumors with carbon ions was reported by Miyamoto et al. 
(76). The first stage phase I/II trial using 18 fractions over 6 weeks 
for 47 patients and the second one using nine fractions over 
3 weeks for 34 patients were conducted by the dose-escalation 
method from 59.4 to 95.4 GyE in incremental steps of 10% and 
from 68.4 to 79.2 GyE, respectively. The local control rates in the 
first and second trials were 64 and 84%, respectively. The doses 
greater than 86.4 GyE at 18 fractions and 72 GyE at nine frac-
tions achieved a local control of 90 and 95%, respectively. Grade 
3 radiation pneumonitis occurred in three of 81 patients, but they 
fully recovered.
Building upon this experience, Miyamoto et al. further treated 
29 Stage 1A and 21 Stage 1B patients who were treated with 
72 GyE in nine fractions over 3 weeks (77). There was 1 in-field 
(Stage 1A) and 1 margin (Stage 1B) failure. Two- and 5-year 
actuarial local control rates were 98 and 95%, respectively. There 
was one grade 3 late skin reaction. A further phase II study using 
a regimen of a fixed dose of 52.8 GyE for T1 tumors and 60 GyE 
for T2 tumors in four fractions over 1 week was performed (78). 
The local control rate at 5 years for all patients was 90% (T1: 98%, 
T2: 80%). No grade 3 or higher toxicities were seen. Currently, a 
dose-escalation study for single-fraction treatment is underway 
at the NIRS, where initial results have shown higher local control 
and survival rates with minimal toxicity (79). A comparison of 
the outcomes of treating NSCLC with different modalities is 
shown in Table 2.
A recent meta-analysis compared particle beam therapies and 
SBRT/SABR versus CFRT (81). Five studies with proton therapy 
and three studies with carbon-ion therapy were included. Due to 
the limited number of patients available for analysis, no signifi-
cant results were able to be obtained for locally advanced NSCLC; 
however, statistical comparisons were able to be made for stage I 
tumors. They summarized that CFRT had worse overall survival 
and disease-free survival compared to SBRT/SABR and particle 
beam therapies. The corrected pooled estimates for 5-year overall 
survival and DFS rates were 19 and 43% for CFRT, 42 and 63% for 
SBRT/SABR, 40 and 52% for protons, and 42 and 64%for carbon 
ions, respectively. Lastly, adverse events appeared to be reduced 
by using particle therapies compared to photon therapies.
These results document that high 2- to 5-year local control 
rates of Stage I NSCLC are being achieved by several methods. 
The carbon-ion therapy 5-year local control results are >95% 
with minimal toxicity. The 2-year proton local control rates are 
similar to those by SBRT/SABR but evidently with lesser risk of 
complications. Longer follow-up is required to assess the clinical 
efficacy of these three modalities.
Liver Cancer
Fukumitsu et al. treated 51 HCC patients with protons to a total 
dose of 66 GyE in 10 fractions (82). Patients were Child–Pugh 
class A or B and whose tumors were ≤10 cm (88% ≤5 cm), 39% 
of patients had multiple tumors and were ≥2  cm from porta 
hepatitis and GI tract. The 3- and 5-year local control rates were 
95 and 88%, respectively. Alpha fetal protein levels dropped from 
97 ng/mL before treatment to 16 ng/mL afterwards (p < 0.0001). 
Patients experienced only minor acute reactions of Grade 1 or 
less, and three patients experienced late sequelae of Grade 2 or 
higher.
Chiba et  al. reported on their results using proton beam 
therapy to treat 162 patients with HCC with a total of 192 lesions 
(83). The median total dose delivered was 72 GyE in 16 fractions 
over 29 days. Eighty-three percentage of the lesions were <5 cm 
in size. The 5-year local control rate was 87%. Thirteen tumors 
locally recurred between 7 and 43 months (median, 21 months) 
after the completion of the irradiation. Maximal diameter of 
tumors that had recurred was median 4.7 cm ranging from 2.0 
to 7.0  cm before irradiation. Five patients had late sequelae of 
grade 2 or higher.
Bush et  al. performed a phase II trial in which 76 patients 
received 63  GyE in 15 fractions over 3  weeks (84). The mean 
tumor size was 5.5 cm. Fifteen patients (20%) experienced local 
treatment failure. Only three patients developed solitary local 
failure, the majority (36%) developed new lesions within the liver. 
No patients developed RILD.
TABLe 2 | Non-small cell lung cancer.
Reference Radiation Dose Gye Dose/Fx Gye Stage n Local control (%) Late toxicity ≥grade 3
Timmerman et al. (10) X
60 20 T1
70 89 at 3 years
10% peripheral
66 23 T2 27% central
Timmerman et al. (29) X 54 18 T1–2a 59 98 at 3 years 15%
Baba et al. (80) X 44–52 11–13 T1–2 124 80 at 3 years 3%
Bush et al. (73) P 51–60 5.1–60 T1 68 86 at 4 years None
T2 45 at 4 years
Nihei et al. (74) P 70–94 3.5–4.9
T1a
T1b
37
100 at 2 years
90 at 2 years
None 15%
Hata et al. (75) P 50–60 5–6 T1a 21 100 at 2 years None
T1b 90 at 2 years
Miyamoto et al. (76) C
59.4–95.4
68.4–79.2
3.3–5.3
7.6–8.8
T1–2 81 76 at 5 years None
Miyamoto et al. (77) C 72 8 T1a–b 50 95 at 5 years 2%
Miyamoto et al. (78) C
52.8
60
13.2
15
T1
T2
79
98 at 5 years
80 at 5 years
None
X, photon therapy; P, proton therapy; C, carbon-ion therapy; Fx, fraction; GyE, gray or gray equivalent; n, patient number.
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Komatsu et al. published a retrospective analysis of 343 patients 
treated with either protons (242 patients) or carbon ions (101 
patients) (85). Eight protocols for proton therapy (52.8–84 GyE in 
4–38 fractions) and four protocols for carbon-ion therapy (52.8–
76 GyE in 4–20 fractions) were used during the study period. The 
5-year local control rate was 90% for proton and 93% for carbon 
ions. Univariate analysis identified tumor size as an independ-
ent risk factor for local recurrence. Grade ≥3 late toxicities were 
observed in eight patients on proton therapy and in four patients 
on carbon-ion therapy, and 4 of 12 patients were diagnosed with 
RILD. No patients died of treatment-related toxicity.
Kato et al. presented results of 24 patients treated on a dose-
escalation trial (49.5–79.5 GyE in dose increments of 10% in a 
fixed 15 fraction setting within 5 weeks) (86). The overall local 
control rate was 92, 81, and 81% at 1, 3, and 5 years, respectively. 
No local failures were seen at a dose level of 72 GyE or higher. 
Except for one early skin reaction, no Grade 3 or worse adverse 
effects occurred at any dose level from 49.5 to 79.5 GyE. More 
recently, a four-fraction regimen has been investigated at NIRS. 
Sixty-nine patients have been treated using this regimen with a 
reported 5-year local control rate of 81% (79). An accelerated 
schedule of two fractions in 2  days is being studied further. 
Another dose-escalation trial is currently underway by Combs 
et al. at the HIT (87). The Prometheus trial escalates the dose from 
40 to 56 GyE in four fractions (87).
A comparison of the outcomes of treating HCC with different 
modalities is shown in Table 3. At present, the clinical results of 
protons appear to be equivalent to those of carbon therapy. It will 
be important to determine the long-term functional status of the 
liver following dose escalation.
Prostate Cancer
Proton ± photon therapy was used to treat 1255 patients at Loma 
Linda University (88). The patients were stage I–IIIA who had no 
prior surgery or hormone therapy. Radiation dose was 74 GyE 
in 37 fractions for patients receiving protons only. The 5- and 
10-year biochemical no evidence of disease (bNED) was 75 
and 73%, respectively. The rate of grades 3–4 rectal and bladder 
complications was 1%.
The first phase III clinical trial of photons versus protons 
was conducted by Shipley et al. (89). A total of 189 patients with 
stages T3–T4 were initially treated with 50.4 Gy by photons to the 
prostate and pelvic nodes followed by either a photon boost to 
67.2 Gy or a proton boost to 75.6 GyE. Patients did not receive any 
concomitant or adjuvant hormone therapy. The local control at 5 
and 8 years for the photon arm were 80 and 60%, respectively, and 
for the proton arm were 92 and 77%, respectively. Complications 
in the photon and proton arms at 8 years were as follows: persis-
tent rectal bleeding 2 versus 9%; urethral stricture 2 versus 4%, 
and hematuria 2 versus 2%.
A phase III trial was performed at MGH and Loma Linda 
University, which randomly assigned patients with T1b–T2b and 
PSA≤15 ng/mL to treatment by proton beams to the prostate to 
19.8 or 28.8 GyE followed by 50.4 Gy with photons to the pelvis 
(90). Dose fractionation was 1.8 Gy/fraction for the entire regi-
men. A total of 393 men were randomized. The 10-year ASTRO 
biochemical failure rates were 32% for conventional dose and 
17% for high-dose radiation therapy. Dose escalation also was 
shown to benefit patients with low-risk disease. Two percentage 
of patients in both arms experienced late grade ≥3 genitourinary 
toxicity, and 1% of patients in the high-dose arm experienced late 
grade ≥3 gastrointestinal toxicity.
Recently, prospective proton-only trials have been performed 
at the University of Florida (91). A total of 211 patients were 
enrolled and received 78 GyE in 39 fractions for low-risk disease 
(N = 89), dose escalation from 78 to 82 GyE for intermediate-
risk disease (N = 82), and 78 GyE with concomitant docetaxel 
followed by androgen deprivation for high-risk disease (N = 40). 
With early follow-up of 2  years, progression-free survival was 
99% for the entire population (100% for low-risk, 99% for 
TABLe 3 | Hepatocellular carcinoma.
Reference Radiation Dose Gye Dose/Fx Gye Stage Size (Ave) n Local control (%) Late toxicity ≥grade 3
Andolino et al. (31) X
36–48
40
13–16
8
CPC-A
CPC-B
3.2 cm
36
24
90 at 2 years 35% heme/liver
Bujold et al. (32) X 24–54 4–9 CPC-A 7.2 cm 102 87 at 1 year 30% (7 G5)
Culleton et al. (33) X 30 5
CPC-B
CPC-C
5.1 cm
28
1
55 at 1 year 63% ↑CP ≥2
Fukumitsu et al. (82) P 66 6.6 CPC-A
CPC-B
2.8 cm 51 88 at 5 years 1 Lung
Chiba et al. (83) P 72 4.5 CPC-A–C 3.8 cm 162 87 at 5 years 3% ≥G2
Bush et al. (84) P 63 4.2 CPC-A–C 5.5 cm 76 80 (2–60 m) None
Komatsu et al. (85)
P
C
52.8–84
52.8–76
2–13.2
3.8–13.2
CPC-A–C <5 cm 74% 242
101
90 at 5 years
93 at 5 years
3%
4%
Kato et al. (86) C 49.5–79.5 3.3–5.3 CPC-A–B 5 cm 24 81 at 5 years 25% ↑CP ≥2
X, photon therapy; P, proton therapy; C, carbon-ion therapy; Fx, fraction; GyE, gray or gray equivalent; n, patient number; CPC, Child–Pugh Class.
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intermediate-risk and 94% for high-risk). Only 1.9% Grade 3 GU 
symptoms and <0.5% Grade 3 GI toxicities were observed.
Several carbon-ion dose-escalation studies have been 
performed at the NIRS since 1995. These early trials were sum-
marized by Tsuji et al. (92). The two previous Phase I/II studies 
performed dose escalation from the initial dose of 54.0  GyE 
in 20 fractions to 72.0 GyE in 20 fractions in 10% increments 
followed by fixed radiation dose of 66.0  GyE in 20 fractions. 
A total of 201 patients were analyzed at the 66.0  GyE dose 
level with a median follow-up of 30 months. The bNED for the 
low-risk patients was 100% and for the high-risk patients was 
81% at 5 years. In the first Phase I/II study, 6 out of 14 patients 
treated with a high target dose (72.0 GyE) developed Grade 3 
morbidities of the rectum or genitourinary system. At the 66.0-
GyE dose level, no Grade 3 or higher toxicities were observed in 
either the rectum or genitourinary system, and the incidences of 
Grade 2 rectum or genitourinary morbidity were only 1.0 and 
6.0%, respectively.
More recently, a total dose of 57.6 GyE in 16 fractions has 
been explored (93). A total of 664 patients (250 patients at 
66.0 GyE in 20 fractions; 216 63.0 GyE in 20 fractions; 198 in 
57.6 GyE in 16 fractions) with at least 1-year follow-up were 
analyzed in regard to late radiation toxicity. The 5-year bio-
chemical relapse-free survival was 90% for the entire group. 
The 5-year BRF of patients treated with 16 fractions was 89% 
compared with 90% for patients treated with 20 fractions. Per 
risk group, the 5-year BRF was 90, 97, and 88% for low-, inter-
mediate, and high-risk patients (94). No grade 3 or higher GI 
toxicity was seen in any of the groups and only one grade 3 GU 
toxicity was seen in the 20 fraction regimen and no grade 3 or 
higher GU adverse effects were seen in the 16 fraction regimen. 
Lately, patients have been treated with the scanning beam in the 
new NIRS facility with 12 fractions in 3 weeks (79). Also the 
HIT has conducted a randomized phase II trial using protons 
or carbon ions treating with a 66 GyE in 20 fractions and the 
results are still pending (95).
A comparison of the outcomes of treating prostate cancer with 
different modalities is shown in Table 4.
Cost-effectiveness of Hypofractionated 
Therapy
Due to the aging of the population in industrialized countries, 
the number of patients who develop malignancies is expected to 
increase. With more patients receiving cancer-directed therapies, 
this is predicted to become a major burden for health care systems 
(96). There has been increasing pressure within the medical com-
munity to identify and promote more cost-effective treatment 
modalities. A significant percentage of the cost of cancer therapy 
is due to drug therapies (97). This highlights the growing need for 
a value-based system that considers cost-effectiveness in deter-
mining cancer drug prices. There is a lack of correlation between 
drug efficacy and cost, with prices remaining high despite the 
entrance of competitive agents to the market (98).
The incremental cost-effectiveness ratio (ICER) is a statistic 
used in cost-effectiveness analysis to summarize the cost-
effectiveness of a health care intervention. It is defined by the 
difference in cost between two possible interventions, divided by 
the difference in their effect. It represents the average incremental 
cost associated with one additional unit of the measure of effect.
Using an ICER approach, actually, radiation therapy is an 
extremely cost-effective cancer therapeutic option in compari-
son to systemic modalities. For example, in using improvement 
in 2-year overall survival as the heath outcome effect, the ICER 
is ~$3,800 for bevacizumab for the treatment of NSCLC (99), 
~$4,800 for pemetrexed for the treatment of NSCLC (100), 
~$3,700 for imatinib for the treatment of chronic myeloid leuke-
mia (101), compared to a significantly reduced cost for carbon-
ion therapy for recurrent colorectal adenocarcinoma (102).
Cost-effective analysis of various hypofractionated regimens for 
different disease sites has been performed. For patients with stage I 
NSCLC, Shah et al. analyzed the cost-effectiveness of SBRT/SABR 
versus surgical resection (103). The mean costs and quality-adjusted 
life expectancies for SBRT/SABR, wedge resection, and lobectomy 
were calculated. For patients determined to be marginally oper-
able, SBRT/SABR was determined to be the most cost-effective 
strategy. Mitera et al. compared conventional versus SBRT/SABR 
for medically inoperable stage I NSCLC (104). Overall survival 
TABLe 4 | Prostate cancer.
Reference Radiation Dose Gye Dose/Fx Gye Stage n Local control or bNeD% Late toxicity 
≥grade 3
Madsen et al. (45) X 33.5 6.7
≤T2a
PSA≤10
GS≤6
40 bNED 90% at 4 years
G2 GU 20%
G2 GI 7.5%
King et al. (46) X 36.25 7.25 ≤T2b
PSA≤10
GS≤7 (3 + 4)
67 bNED 94% at 4 years GU 3.5%
GI 0%
Katz et al. (47) X 35–36.25 7–7.25
69% low
27% intermediate
4% high
304
bNED 97% at 5 years
bNED 91% at 5 years
bNED 74% at 5 years
GU 2.5%
G2 GI 7%
Boike et al. (50) and Kim et al. (52) X 45–50
50
9–10
10
≤T2b
PSA ≤20
GS ≤7
45
46
bNED 99% at 3.5 years GU 5.5%
GI 6.6%
Slater et al. (88) P ± X 74 2 Low, intermediate, 
high
1225 bNED 75% at 5 years GU, GI 1%
Shipley et al. (89) X + P
X
67.2
75.6
1.9 T3-4, N0-N2, M0 96
93
LC 81% at 5 years
LC 92% at 5 years
GU, GI 2%
GU 4%; GI 9%
Zietman et al. (90) X + P 70.2
79.2
1.8
1.8
≤T2b
PSA ≤15
GS any
197
196
bNED 61% at 5 years
bNED 80% at 5 years
GU 2%; GI 1%
GU 1%; GI 1%
Mendenhall et al. (91) P 78
78–82
78
2
2
2
Low
Intermediate
High
89
82
40
bNED 100% at 2 years
bNED 99% at 2 years
bNED 94% at 2 years
GU 1.9%
GI < 0.5%
Tsuji et al. (92) C
54–72
66
2.7–3.6  
3.3
≤T3
PSA any
GS any
94
201
bNED 92% at 5 years
Six points at 
72 GyE
None at 66 GyE
Okata et al. (93) C 63
57.6
3.15
3.6
≤T3
PSA any
GS any
216
198
bNED 90% at 5 years
bNED 89% at 5 years
1 pt GU at 63 GyE
X, photon therapy; P, proton therapy; C, carbon-ion therapy; Fx, fraction; GyE, gray or gray equivalent; n, patient number; PSA, prostate-specific antigen; bNED, biochemical no 
evidence of disease; LC, local control; GU, genitourinary; GI, gastrointestinal.
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was the primary effectiveness end point used in their calculations. 
ICER per life-year gained for SBRT/SABR versus CFRT was $1,120, 
favoring SBRT/SABR as a cost-effective treatment.
For the treatment of localized prostate cancer, comparisons 
of the costs associated with IMRT versus SBRT/SABR were 
determined. Delivery of SBRT/SABR is technically more labor-
intensive then IMRT; however, treatment is completed in only 
five fractions compared to 39–48 fractions required for IMRT. 
A Markov decision analysis model showed that the mean cost of 
SBRT/SABR is $22,152 versus $35,431 for IMRT (105). A separate 
analysis by Sher et al. confirmed an ICER favoring SBRT/SABR 
compared to IMRT (106). Treatment efficacy, rectal toxicity and 
impotence, and the potential for unseen late effects due to SBRT/
SABR were the critical parameters affecting the outcome of the 
model, highlighting the importance of longer term follow-up to 
better determine these variables.
Recent criticisms in regard to the use of particle therapy for 
the treatment of certain malignancies have been raised (107, 
108). The investment costs are considerably higher than those 
for conventional photon therapy (109). Specifically, comparative 
evidence is lacking on the safety and efficacy of particle therapy 
versus alternative therapies.
Grutters et  al. utilized Markov models to compare treat-
ment with carbon ions, protons, CFRT, and SBRT/SABR for 
the treatment of patients with inoperable stage I NSCLC (110). 
Carbon-ion therapy yielded the most quality-adjusted life years 
per patient of 2.67. Carbon-ion therapy had the highest prob-
ability of being cost-effective at 52%, followed by SBRT/SABR at 
47%, proton therapy at 2%, and CFRT at 0%.
Comparison of the cost-effectiveness of IMRT, SBRT/SABR, 
and protons for the treatment of localized prostate cancer were 
reported by Parthan et al. (111). They found that assuming that 
each treatment modality results in equivalent long-term efficacy, 
SBRT/SABR is more cost-effective in improving quality-adjusted 
survival compared to IMRT or proton therapy. With longer-term 
follow-up data, it will be interesting to see how carbon ions would 
compare in the above analysis. The early efficacy and toxicity sug-
gest that it would compare favorably to SBRT/SABR for treating 
prostate cancer.
The role of cost-effectiveness for particle therapy was excel-
lently reviewed by Pijls-Johannesma et  al. (112). In summary, 
adequate reimbursement is necessary to support such innovative 
yet costly treatments. Further incorporation of hypofractionated 
regimens for particle therapy would allow for a higher capacity 
of patients treated. Currently, the billing model within the United 
States reimburses per fraction delivered, therefore, motivating 
more prolonged treatment regimens to be employed. Protons 
currently share this same model, thereby limiting its utilization. 
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By potentially promoting reimbursement by treatment course for 
heavy-ion therapy, promotion of higher capacity by treating more 
patients with fewer fractions could be adopted.
DiSCUSSiON AND FUTURe 
CONSiDeRATiONS
As shown in this review, using more hypofractionated regimens 
for photon therapy have resulted in high control rates with 
minimal normal tissue toxicity. Stereotactic ablative approaches 
with X-rays have already become the standard of care for patients 
with inoperative stage I NSCLC. Promising early clinical results 
highlight the trend to utilize more hypofractionated treatments 
for other disease sites.
The potential for the further improvement in treatment 
outcomes by using particle therapy is also generating excitement. 
Carbon ions, in particular, are attractive due to their superior 
physical dose distribution, higher RBE, and increased effective-
ness in hypoxic tumors, which is expected to generate clinical 
gains. A systematic approach has been carried out at NIRS and 
GSI/HIT to determine the optimal dose fractionation regimens 
for various disease sites, resulting in the majority of tumors being 
treated with hypofractionated schemes.
Comparing data for different particle treatments is challenging 
due to different dose regimens, fractionated regimens, and different 
RBE calculation for carbon ions in different centers. It has been pro-
posed that in the future more prospective clinical trials are necessary 
to confirm the theoretical benefit of carbon ions. The studies should 
focus on treatment-related toxicity in addition to local tumor control 
and survival. However, there is ongoing debate on the necessity to 
conduct randomized trials before implementing new technologies 
(57, 112–114). Some argue that based on the principles of equipoise 
between photons and particle therapy, randomization of patients 
between the two arms could be unethical (67). Further discussion 
on these issues should be addressed in future international working 
groups. In addition, more research into the costs and the optimal 
way in which to define reimbursement levels for carbon-ion therapy 
are critical for more widespread implementation.
CONCLUSiON
With advances in imaging and treatment delivery techniques, the 
use of more hypofractionated regimens has become more widely 
employed. Hypofractionated treatment approaches are highly 
efficacious and safe for the treatment of certain tumors, more 
cost-effective compared to conventional fractionated approaches, 
are more efficient use of clinical resources, and also are more 
convenient for the patient by greatly reducing their treatment 
course. By utilizing hypofractionated regimens, the potential 
clinical advantage of particle therapy could be achieved.
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